-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shengxiang Biological issued an announcement stating that the company and Gree Real Estate's wholly-owned subsidiary Zhuhai Baolian Asset Management Co.
, Ltd.
Shengxiang Biological said in the announcement that it will complete the aforementioned acquisition with its own funds.
Behind the sufficient cash flow is the surge in performance of Shengxiang Biological in the past year
Because of the industry development opportunities brought about by the new crown epidemic, Shengxiang Bio, which was listed on the Science and Technology Board in August last year, has become the "performance growth king" in the IVD field
.
In 2019, Shengxiang Biological’s annual revenue was approximately 360 million yuan.
In 2020, its operating income rose to 4.
763 billion yuan, a year-on-year increase of 1204%.
It is understood that after the outbreak of the new crown epidemic, Shengxiang Biotechnology has developed a new coronavirus nucleic acid detection kit within a short period of time.
It is one of the top 6 domestic companies that have approved new coronavirus detection products for the market.
At the same time, it is also taking advantage of the development opportunities brought by the epidemic that Shengxiang Biotech is vigorously expanding overseas markets.
According to its first performance report after listing, in 2020, its seven global regional centers will accelerate its layout and its overseas sales channels will further increase.
However, the performance growth brought about by major public health incidents is sporadic and unsustainable.
In the post-epidemic era, how to find the next "outlet" for Shengxiang Biotechnology, which has taken off with the help of new crown detection, is a question that has to be considered
From the outside world, the acquisition of part of the shares of Kehua Biological by Shengxiang Bio is for the purpose of laying out longer-term development
.
It is understood that Kehua Bio is the first listed IVD company in China.
It was listed on the SME board of the Shenzhen Stock Exchange in July 2004.
It used to be the in-vitro diagnostic company with the largest production volume, the highest market occupancy rate and the most complete categories in China.
In terms of financial data, from 2018 to 2020 and the first quarter of 2021, the company achieved operating income of 1.
99 billion yuan, 2.
414 billion yuan, 4.
155 billion yuan and 1.
453 billion yuan, respectively; net profit attributable to shareholders of listed companies was 2.
08.
100 million yuan, 202 million yuan, 675 million yuan, and 342 million yuan
.
According to industry insiders, in general, in the in vitro diagnostic industry, Kehua Biology’s advantageous areas-biochemical diagnosis and immunodiagnosis, and Shengxiang Biotech’s advantageous areas-nucleic acid detection are complementary to each other, and both parties are in the instrument, equipment, Channels can achieve a win-win chemical reaction
.
"Nucleic acid detection is more accurate, but biochemical diagnosis and immunodiagnosis are indispensable in many cases.
In this sense, Shengxiang Biology and Kehua Biology have a lot of room for cooperation
.
"
Shengxiang Biology pointed out in the announcement that the company’s acquisition of Kehua Biology’s equity will enable the two parties to complement each other's advantages in technology platforms, product lines, channels, and markets
.
This transaction is conducive to further improving the disease solutions and full-scenario system solutions of both parties, and building a more comprehensive and comprehensive new ecosystem of in vitro diagnostic applications, which will effectively promote the construction of the domestic medical and health system, and will accelerate the globalization Export the "Chinese solution" in the medical and health field, promote the development of China's in vitro diagnostic industry to a higher level and higher level, and seize the commanding heights of the global industry
.
In addition, since Shengxiang Biotech is also engaged in in vitro diagnostics, and the company's products are mainly focused on the field of molecular diagnostics, there is competition in the same industry with Kehua Biotech.
In this regard, Shengxiang Biotech promises to solve the problem of horizontal competition within 3 years after the signing of the agreement
.
(Medical Valley)
